This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Summit Therapeutics Stock: Sell or Hold Before Q3 Earnings?
by Zacks Equity Research
Devoid of any marketed drug in its portfolio, investors will likely focus on SMMT's pipeline updates when it reports third-quarter results this month.
Summit Stock Skyrockets Nearly 700% YTD: Time to Sell or Hold?
by Zacks Equity Research
The rally in SMMT stock is driven by encouraging updates on its oncology candidate, which has the potential to become the next standard of care in the NSCLC space.
ARCT Stock Up as Updated COVID-19 Jab Betters PFE & BNTX's Comirnaty
by Zacks Equity Research
Arcturus stock gains as the company reports that its sa-mRNA COVID-19 vaccine, ARCT-154, shows superior efficacy compared with treatment with Comirnaty.
PFE & BNTX Get Positive CHMP Opinion for Updated COVID-19 Jab
by Zacks Equity Research
The Committee for Medicinal Products for Human Use recommends marketing authorization for Pfizer and BioNTech's updated version of mRNA COVID-19 jab, Comirnaty.
BioNTech (BNTX) Stock Jumps 5.8%: Will It Continue to Soar?
by Zacks Equity Research
BioNTech (BNTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
MRNA Gets Positive CHMP Opinion for Updated COVID-19 Jab
by Zacks Equity Research
The Committee for Medicinal Products for Human Use recommends marketing authorization for Moderna's updated mRNA COVID-19 jab, Spikevax.
FDA Approves Pfizer & Moderna's Updated COVID-19 Jabs
by Sundeep Ganoria
On Thursday, the FDA cleared new versions of Pfizer's (PFE) and Moderna's (MRNA) COVID-19 vaccines that are designed to match COVID-19 strains currently circulating in the country.
How Should You Play Pfizer (PFE) After COVID-Flu Shot Setback?
by Kinjel Shah
After Pfizer's (PFE) better-than-expected second-quarter results and the bullish outlook for the year, investors who own Pfizer's stock may consider staying invested.
Pfizer (PFE), BioNTech COVID-Flu Combo Shot Study Falters
by Zacks Equity Research
Pfizer's (PFE) COVID and flu combination vaccine demonstrates a continued trend of higher responses against influenza A but fails to show non-inferiority against the influenza B strain.
Pfizer (PFE) Beats on Q2 Earnings & Sales, Raises 2024 View
by Zacks Equity Research
Pfizer (PFE) beats second-quarter estimates for earnings and sales. It raises 2024 earnings as well as revenue expectations.
Pfizer (PFE) Q2 Earnings Coming Up: What Should Investors Do?
by Kinjel Shah
Pfizer (PFE) expects its operational revenues to improve, driven by its in-line products like Vyndaqel, new launches like Abrysvo and newly acquired products, including those acquired from Seagen
Pfizer (PFE) Stock Falls in a Year: Time to Buy, Sell or Hold?
by Kinjel Shah
Pfizer (PFE) expects its operational revenues to improve, driven by its in-line products like Vyndaqel, new launches like Abrysvo and newly acquired products, including those acquired from Seagen.
Pfizer (PFE), BioNTech's Updated COVID-19 Jab Gets CHMP Nod
by Zacks Equity Research
Pfizer (PFE) and BioNTech's Omicron JN.1-adapted COVID-19 vaccine gets the Committee for Medicinal Products for Human Use's positive opinion recommending marketing authorization.
Moderna's (MRNA) Next-Gen COVID-19 Jab Study Meets Efficacy Goal
by Zacks Equity Research
Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID-19 vaccine achieved non-inferior vaccine efficacy against COVID-19 when compared with its previously approved bivalent COVID-19 vaccine.
Moderna (MRNA) COVID-Flu Combo Jab Meets Late-Stage Study Goal
by Zacks Equity Research
Data from a late-stage study shows that Moderna's (MRNA) experimental COVID-19-influenza combination vaccine generates higher immune responses when compared to co-administered licensed flu and COVID vaccines.
Why Earnings Season Could Be Great for BioNTech (BNTX)
by Zacks Equity Research
BioNTech (BNTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Pfizer (PFE) Q1 Earnings & Sales Top, EPS Guidance Raised
by Zacks Equity Research
Pfizer (PFE) beats first-quarter estimates for earnings and sales. It raises 2024 earnings guidance while retaining revenue expectations.
BioNTech (BNTX) to Report Q1 Earnings: Is a Beat in Store?
by Zacks Equity Research
On BioNTech's (BNTX) first-quarter 2024 earnings call, investors' focus is likely to be on the updates related to its pipeline development now that the pandemic is over.
Here's How to Play Pfizer (PFE) Stock Ahead of Q1 Earnings
by Kinjel Shah
Pfizer (PFE) expects its operational revenues to improve, driven by its in-line products like Vyndaqel, new launches like Abrysvo and newly acquired products, including those acquired from Seagen.
Will Pfizer's (PFE) New Drugs Provide a Boost to 2024 Sales?
by Zacks Equity Research
Pfizer (PFE) expects its operational revenues to improve, driven by its in-line products like Vyndaqel, new launches like Abrysvo and newly acquired products, including those acquired from Seagen.
Will Novavax's (NVAX) Strategic Reshaping Curb Cash Burn?
by Zacks Equity Research
To extend its existing cash runway and curb cash burn, Novavax (NVAX) initiates multiple restructuring initiatives that are aimed at lowering operating expenses and enhancing profitability.
Moderna (MRNA) Posts Upbeat Data From Next-Gen COVID Jab Study
by Zacks Equity Research
Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID vaccine induces a more robust immune response compared with its previously approved bivalent COVID vaccine.
Pfizer (PFE) Q4 Earnings Top, Revenues Miss on COVID Sales Slump
by Zacks Equity Research
Pfizer (PFE) reports mixed fourth-quarter 2023 results. It re-affirms its 2024 sales and earnings guidance provided in December 2023.
Will New Drugs Drive Pfizer (PFE) Sales in Q4 Earnings?
by Zacks Equity Research
Investor focus is likely to be on the sales numbers of Pfizer's (PFE) several newly launched drugs like Abrysvo, Velsipity, Penbraya as well as newly acquired products like Nurtec and Oxbryta on the fourth-quarter earnings call.
Pfizer (PFE) Stock Sinks on Weak 2024 View as COVID Sales Fall
by Zacks Equity Research
Pfizer's (PFE) shares decline almost 7% in response to the muted guidance for 2024. Revenues are expected to be in the range of $58.5 to $61.5 billion, while adjusted EPS is expected in the range of $2.05 to $2.25.